Germany's Grünenthal to acquire Almirall's Mexican operations

16 March 2016

German family-owned drugmaker Grünenthal Group has entered into a definitive agreement with Spain’s leading pharma company Almirall (ALM: MC) under which Grünenthal will acquire 100% of the share capital of Almirall de Mexico.

The transaction also includes an agreement to perpetually license a portfolio of mainly international products with around 17.5 million euros ($19.4 million) net sales in 2015 in Mexico. The transaction, financial terms of which were not disclosed, will be completed in early May 2016.

A key element of Grünenthal’s strategy is to significantly expand the business in Latin America – focusing on the key markets Mexico and Brazil – over the next years through internal growth, partnering or acquisitions. With more than 50 years presence in the region, the company is committed to further expand its operations in Latin America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK